[go: up one dir, main page]

AR114827A1 - Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida - Google Patents

Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida

Info

Publication number
AR114827A1
AR114827A1 ARP190101056A ARP190101056A AR114827A1 AR 114827 A1 AR114827 A1 AR 114827A1 AR P190101056 A ARP190101056 A AR P190101056A AR P190101056 A ARP190101056 A AR P190101056A AR 114827 A1 AR114827 A1 AR 114827A1
Authority
AR
Argentina
Prior art keywords
indacen
sodium salt
sulfonamida
hexahidro
isopropil
Prior art date
Application number
ARP190101056A
Other languages
English (en)
Inventor
Samuel Alexander Stratford
Ro Gancedo Susana Del
Angus Macleod
David Miller
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of AR114827A1 publication Critical patent/AR114827A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Una sal sódica de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1H-pirazol-3-sulfonamida o un hidrato o solvato de esta. Reivindicación 5: La sal de cualquiera de las reivindicaciones de 1 a 4, en donde la sal es una sal monosódica cristalina de monohidrato de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1H-pirazol-3-sulfonamida. Reivindicación 6: Una forma polimórfica de la sal de la reivindicación 5 que tiene un espectro de XRPD que comprende picos a aproximadamente: 4,3 º2q, 8,7 º2q y 20,6 º2q.
ARP190101056A 2018-04-23 2019-04-23 Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida AR114827A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1806578.9A GB201806578D0 (en) 2018-04-23 2018-04-23 Novel compound

Publications (1)

Publication Number Publication Date
AR114827A1 true AR114827A1 (es) 2020-10-21

Family

ID=62236309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101056A AR114827A1 (es) 2018-04-23 2019-04-23 Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida

Country Status (28)

Country Link
US (2) US10973803B2 (es)
EP (2) EP3606909B1 (es)
JP (1) JP7382958B2 (es)
KR (1) KR20210005589A (es)
CN (1) CN112020495B (es)
AR (1) AR114827A1 (es)
AU (1) AU2019257973A1 (es)
BR (1) BR112020021650A2 (es)
CA (1) CA3097832A1 (es)
CY (1) CY1123260T1 (es)
DK (1) DK3606909T3 (es)
ES (1) ES2811228T3 (es)
GB (1) GB201806578D0 (es)
HR (1) HRP20201263T1 (es)
HU (1) HUE050369T2 (es)
LT (1) LT3606909T (es)
MA (2) MA51082A (es)
MD (1) MD3606909T2 (es)
ME (1) ME03822B (es)
MX (1) MX2020011196A (es)
PL (1) PL3606909T3 (es)
PT (1) PT3606909T (es)
RS (1) RS60646B1 (es)
SI (1) SI3606909T1 (es)
SM (1) SMT202000448T1 (es)
TW (1) TW201943704A (es)
UY (1) UY38186A (es)
WO (1) WO2019206871A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3571187B1 (en) 2017-01-23 2023-11-22 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
BR112019024831A2 (pt) 2017-05-24 2020-06-09 The University Of Queensland composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CA3071150A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
BR112020002906A2 (pt) 2017-08-15 2020-08-04 Inflazome Limited novos compostos de sulfonamida-carboxamida
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020115098A (ru) 2017-11-09 2021-12-10 Инфлазоум Лимитед Соединения новых сульфонамидкарбоксамидов
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
PE20211049A1 (es) 2018-07-20 2021-06-04 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
KR20210034596A (ko) 2018-07-20 2021-03-30 에프. 호프만-라 로슈 아게 인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2023500925A (ja) * 2019-11-07 2023-01-11 インフレイゾーム リミテッド 神経炎症または炎症性脳疾患の処置および予防
JP2023501319A (ja) * 2019-11-07 2023-01-18 インフレイゾーム リミテッド 神経変性疾患の処置および予防
EP4054564A1 (en) * 2019-11-07 2022-09-14 Inflazome Limited Treatment of autoinflammatory disorders
WO2021089781A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
WO2021089776A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of a traumatic brain disorder
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
WO2001019390A1 (en) * 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
CN104023729A (zh) * 2011-09-02 2014-09-03 协和发酵麒麟株式会社 趋化因子受体活性调节剂
AU2016222278B2 (en) 2015-02-16 2020-07-09 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
ES2855732T3 (es) 2016-04-18 2021-09-24 Novartis Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
ES2940611T3 (es) 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
ME03822B (me) 2021-04-20
DK3606909T3 (da) 2020-08-24
MX2020011196A (es) 2020-11-13
EP3722281A1 (en) 2020-10-14
CY1123260T1 (el) 2021-12-31
RS60646B1 (sr) 2020-09-30
US10973803B2 (en) 2021-04-13
WO2019206871A1 (en) 2019-10-31
CA3097832A1 (en) 2019-10-31
LT3606909T (lt) 2020-10-12
SI3606909T1 (sl) 2020-09-30
US20210315862A1 (en) 2021-10-14
EP3606909A1 (en) 2020-02-12
SMT202000448T1 (it) 2020-09-10
EP3606909B1 (en) 2020-05-27
TW201943704A (zh) 2019-11-16
CN112020495B (zh) 2024-05-17
MD3606909T2 (ro) 2020-08-31
US20200237723A1 (en) 2020-07-30
UY38186A (es) 2019-11-29
HUE050369T2 (hu) 2020-11-30
KR20210005589A (ko) 2021-01-14
MA51082A (fr) 2021-05-19
PT3606909T (pt) 2020-07-09
ES2811228T3 (es) 2021-03-11
GB201806578D0 (en) 2018-06-06
BR112020021650A2 (pt) 2021-01-26
JP2021522195A (ja) 2021-08-30
JP7382958B2 (ja) 2023-11-17
AU2019257973A1 (en) 2020-11-19
HRP20201263T1 (hr) 2021-02-05
MA48051B1 (fr) 2020-08-31
PL3606909T3 (pl) 2020-11-16
CN112020495A (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
AR114827A1 (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
EP3860987C0 (en) PESTICIDE-ACTIVE AZOLE-AMIDE COMPOUNDS
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
EA201892128A1 (ru) Гетероциклические амиды, полезные в качестве модуляторов
AR112276A1 (es) Polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona
EA201992235A1 (ru) Синтез ингибитора mcl-1
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
MX381911B (es) Derivados heterociclicos y uso de los mismos.
AR110768A1 (es) Formas cristalinas de tenofovir alafenamida
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
JOP20200081A1 (ar) أملاح من مشتقات بيرولوتريازين مفيدة بوصفها مثبطات لـ tam
AR105967A1 (es) Sales de un inhibidor de pim quinasa
EA201690911A1 (ru) Соединения диметилбензойной кислоты
IL277197B (en) Efficient convolutional engine
EA201592183A1 (ru) Ингибиторы bace
LT3833665T (lt) Diazabiciklooktanonai kaip serino beta-laktamazės inhibitoriai
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
DK3782986T3 (da) Heterocyklisk forbindelse
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
EP3856174A4 (en) HDAC1, 2 INHIBITORS
AR114270A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
EA202190989A1 (ru) Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений

Legal Events

Date Code Title Description
FA Abandonment or withdrawal